An ALK5 inhibitor, vactosertib, can down-regulate the EMT markers (Vimentin, Snail, Slug, Twist) thus being considered as an option to prevent metastasis, when radiotherapy is applied to breast cancer patients (53). Here, VIM is linked to breast carcinoma.